Eli Lilly and Company confirmed it will release fourth-quarter 2025 financial results on February 4, 2026, with a live conference call at 10 a.m. Eastern Time. The webcast link will be hosted on Lilly’s investor relations site and archived for replay, ensuring broad access for institutional and retail investors. This early notice allows stakeholders to prepare questions on revenue drivers, margin trends and cash-flow expectations before the data is published.

Lilly remains the dominant force in the global obesity and diabetes markets through its GLP-1 franchise. The company is on track to launch its first oral GLP-1 obesity therapy in Q2 2026, a milestone expected to lower barriers to treatment and drive accelerated patient adoption outside the U.S. Management has projected mid-teens percentage growth in the obesity portfolio for 2026, even as pricing pressure intensifies in select ex-U.S. markets. Analysts highlight that widening access and simplified dosing could expand Lilly’s total addressable market by over 20%, solidifying its leadership position.

Beyond GLP-1 therapies, Lilly’s late-stage pipeline includes candidates targeting Alzheimer’s disease, oncology and cardiovascular indications. The company reports over 40 active clinical trials and anticipates at least two new approvals by year-end 2027. Consensus estimates call for earnings growth exceeding 32% in 2026, driven by rising volume in core franchises and operating leverage. Lilly’s commitment to inclusive trial enrollment and tiered pricing programs further underpins its financial resilience and long-term revenue visibility.